SCHEMBL1471814

SCHEMBL1471814

NC(=NS(=O)(=O)c1cc(Cl)c(Oc2ccc([N+](=O)[O-])cc2)c(Cl)c1)c1ccc(Cl)cc1

nearest known ligand 0.56

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.56
LMNA P02545 2/20 0.56
SMN1; SMN2 Q16637 1/20 0.56
MAPT P10636 3/20 0.48
GAA P10253 2/20 0.48
POLB P06746 2/20 0.48
NPSR1 Q6W5P4 1/20 0.48
F2 P00734 7/20 0.45
PRSS1 P07477 7/20 0.45
PRSS2 P07478 7/20 0.45
PRSS3 P35030 7/20 0.45
FAAH O00519 1/20 0.43
MGLL Q99685 1/20 0.43
FLT1 P17948 1/20 0.42
FLT4 P35916 1/20 0.42
KDR P35968 1/20 0.42
THRA P10827 2/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5798194 0.92 SMN1; SMN2 (0.62) ALDH1A1LMNASMN1; SMN2MAPTPOLB
SCHEMBL1471503 0.90 MAPT (0.53) ALDH1A1LMNASMN1; SMN2MAPTGAA
SCHEMBL5779046 0.88 THRA (0.56) ALDH1A1LMNASMN1; SMN2MAPTGAA
SCHEMBL1471998 0.84 F2 (0.50) ALDH1A1LMNASMN1; SMN2MAPTGAA
SCHEMBL1472081 0.84 MAPT (0.50) ALDH1A1LMNASMN1; SMN2MAPTF2
SCHEMBL1471421 0.83 F2 (0.47) ALDH1A1LMNASMN1; SMN2GAAF2
SCHEMBL8408914 0.80 MEN1 (0.43) ALDH1A1LMNAMAPTGAAPOLB
SCHEMBL6363615 0.79 ALDH1A1 (0.57) ALDH1A1LMNASMN1; SMN2MAPTGAA
SCHEMBL1471217 0.78 THRA (0.52) ALDH1A1LMNASMN1; SMN2MAPTGAA
SCHEMBL1471812 0.77 FLT1 (0.53) ALDH1A1LMNASMN1; SMN2MAPTGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7915293-B2 Carbocyclic and heterocyclic sulfonamide derivatives, e.g., N-(2-bromo-5-(trifluoromethoxy)phenyl)-3,5-dichloro-4-(2-chloro-4-nitrophenoxy)benzenesulfonamide and 4-(2-(trifluoromethyl)phenoxy)-1-(3-trifluoromethyl)phenylsulfonyl)piperidine; treating proliferative diseases RIGEL PHARMACEUTICALS, INC. (US) 2011-03-29 US claimed
US-20050009871-A1 Ubiquitin ligase inhibitors RIGEL PHARMACEUTICALS, INC. 2005-01-13 US claimed
US-7915293-B2 Carbocyclic and heterocyclic sulfonamide derivatives, e.g., N-(2-bromo-5-(trifluoromethoxy)phenyl)-3,5-dichloro-4-(2-chloro-4-nitrophenoxy)benzenesulfonamide and 4-(2-(trifluoromethyl)phenoxy)-1-(3-trifluoromethyl)phenylsulfonyl)piperidine; treating proliferative diseases RIGEL PHARMACEUTICALS, INC. (US) 2011-03-29 US disclosed
US-20050009871-A1 Ubiquitin ligase inhibitors RIGEL PHARMACEUTICALS, INC. 2005-01-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050009871-A1 Ubiquitin ligase inhibitors NEDD4, STUB1, UBE3A ALDH1A1 1362/4885LMNA 4028/4885SMN1; SMN2 3336/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.